Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 575 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cytopenias Clear all
Completed Phase 2 Interventional

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

NCT00002800
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Neutropenia
Interventions
filgrastim, lintuzumab, cytarabine, etoposide, idarubicin
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

NCT01012492
View directory record Official record
Conditions
AML, ALL, Undifferentiated Leukemia, Biphenotypic Leukemia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts, Refractory Anemia With Excess Blasts-1 (5-10% Blasts), Refractory Anemia With Excess Blasts-2 (10-20% Blasts), Myelodysplastic Syndrome, Unclassified, MDS Associated With Isolated Del (5q)
Interventions
Abatacept
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 17, 2026, 4:53 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04958265
View directory record Official record
Conditions
Atypical Hemolytic Uremic Syndrome
Interventions
Crovalimab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
28 Days to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
3
States / cities
Aurora, Colorado • Omaha, Nebraska • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy

NCT00020371
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific, Neutropenia
Interventions
BMS-247550, filgrastim
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 17, 2026, 4:53 AM EDT
Completed No phase listed Observational

Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children

NCT00118664
View directory record Official record
Conditions
Septic Shock, Thrombocytopenia, Multiple Organ Failure
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
6 Months to 18 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Iowa City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 17, 2026, 4:53 AM EDT
Completed No phase listed Observational

Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients

NCT03262584
View directory record Official record
Conditions
Invasive Fungal Disease, Fever and Neutropenia, Invasive Fungal Infections, Immunocompromised
Interventions
Not listed
Lead sponsor
Karius, Inc.
Industry
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia

NCT00002693
View directory record Official record
Conditions
Leukemia, Neutropenia
Interventions
filgrastim, carboplatin, topotecan hydrochloride
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Oct 17, 2026, 4:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thrombopoietin Levels and Platelet Transfusion in Neonates

NCT00549484
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Not listed
Lead sponsor
Christiana Care Health Services
Other
Eligibility
Up to 6 Months
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 18, 2008 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer

NCT00012376
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Paroxysmal Nocturnal Hemoglobinuria, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Relapsing Chronic Myelogenous Leukemia, Thrombocytopenia, Untreated Adult Acute Myeloid Leukemia
Interventions
bryostatin 1, sargramostim, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura

NCT00002250
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura ( ITP ), HIV Infections
Interventions
CD4-IgG
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

NCT00066599
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma
Interventions
voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Orange, California • San Diego, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

NCT04278924
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Placebo, TAK-079
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Gainesville, Florida • Peoria, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 17, 2026, 4:53 AM EDT
Terminated Phase 3 Interventional

Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome

NCT00004465
View directory record Official record
Conditions
Hemolytic Uremic Syndrome
Interventions
SYNSORB Pk, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 18 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
26
States / cities
Denver, Colorado • Wilmington, Delaware • Atlanta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC

NCT00000711
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Zidovudine, Sargramostim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 17, 2026, 4:53 AM EDT
Terminated Phase 3 Interventional Results available

Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger

NCT04743804
View directory record Official record
Conditions
Thrombotic Microangiopathy
Interventions
Ravulizumab, Placebo, Best Supportive Care
Biological · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Tucson, Arizona • Orange, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Gene Therapy for the Treatment of Fanconi's Anemia Type C

NCT00001399
View directory record Official record
Conditions
Fanconi's Anemia, Pancytopenia
Interventions
Transduced CD34+ Cells
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
5 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects

NCT02281370
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
Eltrombopag, Cyclosporine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 17, 2026, 4:53 AM EDT
Terminated Early Phase 1 Interventional Results available

Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes

NCT00361296
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
K562/GM-CSF cell vaccine
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 17, 2026, 4:53 AM EDT
Terminated Phase 3 Interventional Results available

Daptomycin Versus Placebo in Patients With Neutropenia and Fever

NCT01216241
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
Daptomycin, Saline Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Study of Romiplostim for Chemotherapy Induced Thrombocytopenia

NCT02052882
View directory record Official record
Conditions
Isolated Chemotherapy-induced Thrombocytopenia
Interventions
romiplostim
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 17, 2026, 4:53 AM EDT
Completed No phase listed Observational

Evaluation, Treatment, and Training for Patients With Blood Disorders

NCT00001397
View directory record Official record
Conditions
Hematologic Diseases
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 110 Years
Enrollment
1,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 17, 2026, 4:53 AM EDT
Terminated Phase 1 Interventional Results available

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

NCT00589316
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, CD45-Positive Neoplastic Cells Present, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions
Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate, Iodine I 131 Monoclonal Antibody BC8, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Tacrolimus, Total-Body Irradiation
Procedure · Drug · Radiation + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 17, 2026, 4:53 AM EDT
Completed No phase listed Observational

Use of NGS Cell-free Pathogen Test for Identification of Low Risk Fever & Neutropenia in Pediatric Patients

NCT03530072
View directory record Official record
Conditions
Neutropenia, Fever
Interventions
Karius Test
Diagnostic Test
Lead sponsor
Karius, Inc.
Industry
Eligibility
1 Year to 22 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 17, 2026, 4:53 AM EDT
Not yet recruiting Phase 2 Interventional

Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases

NCT07660783
View directory record Official record
Conditions
Bone Marrow Failure, Hemoglobinopathies, Primary Immune Deficiency (PID), Autoimmune Cytopenia, Immune Dysregulation, Hemophagocytic Lymphohistiocytosis (HLH), Non Malignant Disorders
Interventions
ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 17, 2026, 4:53 AM EDT